论文部分内容阅读
目的:探讨中西医结合方案治疗慢性乙型肝炎(CHB)的临床疗效。方法:76例CHB患者随机分成观察组39例和对照组37例。对照组采用派罗欣180μg/次,1次/周,sc,观察组在此基础上根据不同中医证候加用十味溪黄草颗粒或人参健脾丸。疗程均为48周。观测两组肝功能、中医证候积分、HBV-DNA定量及乙肝病毒血清标志物。结果:疗后24,48周观察组血清HBV-DNA水平低于对照组(P<0.05,P<0.01);疗后12,24,48周观察组中医证候积分明显低于对照组(P<0.01);疗后24,48周观察组门冬氨酸氨基转移酶(AST),丙氨酸氨基转移酶(ALT),总胆红素(TBil)水平低于对照组(P<0.05,P<0.01);疗后48周观察组肝功复常率及HBV-DNA转阴率均优于对照组(P<0.05)。结论:中西医结合治疗CHB较单纯的西医治疗有更明显的临床优势,值得推广使用。
Objective: To explore the clinical efficacy of integrated traditional Chinese and western medicine in the treatment of chronic hepatitis B (CHB). Methods: Sixty-six CHB patients were randomly divided into observation group (39 cases) and control group (37 cases). The control group used Pegasys 180μg / time, once / week, sc, the observation group on this basis, according to different TCM syndromes plus Shiwei Xi Huangcao granules or ginseng spleen pill. The course of treatment was 48 weeks. Two groups of liver function, TCM syndrome score, HBV-DNA quantitative and hepatitis B virus serum markers were observed. Results: At 24, 48 weeks after treatment, serum HBV-DNA levels in the observation group were lower than those in the control group (P <0.05, P <0.01). The scores of TCM syndromes in the observation group at 12, 24 and 48 weeks after treatment were significantly lower than those in the control group <0.01). The levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and total bilirubin (TBil) in the observation group were lower than those in the control group 24 and 48 weeks after treatment (P <0.05, P <0.01). After 48 weeks of treatment, the rate of abnormal liver function and HBV-DNA negative rate in the observation group were better than those in the control group (P <0.05). Conclusion: Integrative Chinese medicine treatment of CHB than simple Western medicine has more obvious clinical advantages, it is worth promoting the use of.